Host cells containing multiple integrating vectors comprising an amplifiable marker
The present invention relates to the production of proteins in host cells, and more particularly to host cells containing multiple integrated copies of an integrating vector comprising an exogenous gene and an amplifiable marker. The present invention further relates to the use of integrating vectors comprising an amplifiable marker. The present invention further provides methods of expressing increased levels of protein in host cells using such vectors.
1 . A host cell comprising a plurality of retroviral vectors, said retroviral vectors comprising in operable association an exogenous promoter, a gene of interest and an amplifiable marker.
2 . The host cell of claim 1 , wherein said amplifiable marker is selected from the group consisting of DHFR and glutamine synthetase.
3 . The host cell of claim 1 , wherein said plurality of retroviral vectors are integrated into at least two chromosomes of said host cell.
4 . The host cell of claim 1 , wherein said plurality of retroviral vectors are integrated into between 2 and 10 chromosomes of said host cell.
5 . The host cell of claim 1 , wherein said retroviral vectors comprise MoMLV elements.
6 . The host cell of claim 1 , wherein said retroviral vector further comprises an IRES element.
7 . The host cell of claim 1 , wherein said retroviral vector comprises at least two genes of interest.
8 . The host cell of claim 7 , wherein said at least two genes of interest are arranged in a polycistronic sequence.
9 . The host cell of claim 7 , wherein said at least two genes of interest encode an immunoglobulin.
10 . The host cell of claim 9 , wherein said immunoglobulins are selected from the group consisting of IgG, IgA, IgM, IgD, IbE and sIg.
11 . The host cell of claim 1 , wherein said host cell comprises between about 10 and about 100 copies of said retroviral vectors.
12 . The host cell of claim 1 , further comprising at least a second retroviral vector encoding a second gene of interest.
13 . The host cell of claim 1 , wherein said host cell is selected from Chinese hamster ovary cells, baby hamster kidney cells, human 293 cells, and bovine mammary epithelial cells.
14 . The host cell of claim 1 , wherein said retroviral vector further comprises a signal sequence in operable association with said gene of interest.
15 . A method of producing a host cell comprising:
a) providing:
i) host cells; and
ii) a retroviral vector, said retroviral vector comprising in operable association an exogenous promoter, a gene of interest and an amplifiable marker;
b) contacting said host cells with said retroviral vector under conditions such that multiple copies of said retroviral vector integrate into the genome of said host cell to provide a transduced host cell;
c) culturing said transduced host cells under conditions that allow for amplification of said integrated retroviral vectors.
16 . The method of claim 15 , wherein said amplifiable marker is selected from the group consisting of DHFR and glutamine synthetase.
17 . The method of claim 15 , wherein said culturing conditions comprise culturing said transduced host cells in the presence of a selection agent selected from the group consisting of methotrexate, phosphinothricin and methionine sulphoxime.
18 . The method of claim 17 , wherein said culturing conditions further comprises culturing said host cells in increasing concentrations of said selection agent.
19 . The method of claim 15 , wherein multiple copies of said retroviral vectors are integrated into at least two chromosomes of said host cell.
20 . The method of claim 15 , wherein said multiple copies of said retroviral vectors are integrated into between 2 and 10 chromosomes of said host cell.
21 . The method of claim 15 , wherein said retroviral vectors comprise MoMLV elements.
22 . The method of claim 15 , wherein said retroviral vector further comprises an IRES element.
23 . The method of claim 15 , wherein said retroviral vector comprises at least two genes of interest.
24 . The method of claim 23 , wherein said at least two genes of interest are arranged in a polycistronic sequence.
25 . The method of claim 23 , wherein said at least two genes of interest encode an immunoglobulin.
26 . The host cell of claim 25 , wherein said immunoglobulins are selected from the group consisting of IgG, IgA, IgM, IgD, IbE and sIg.
27 . The method of claim 15 , wherein said host cell comprises between about 10 and about 100 copies of said retroviral vectors following said amplification.
28 . The method of claim 15 , wherein said host cell comprises between about 10 and about 1000 copies of said retroviral vectors following said amplification.
29 . The method of claim 15 , wherein said host cell comprises greater than 50 copies of said retroviral vectors following said amplification
30 . The method of claim 15 , wherein said host cell further comprises at least a second retroviral vector encoding a second gene of interest.
31 . The method of claim 15 , wherein said host cell is selected from Chinese hamster ovary cells, baby hamster kidney cells, human 293 cells, and bovine mammary epithelial cells.
32 . The method of claim 15 , wherein said retroviral vector further comprises a signal sequence in operable association with said gene of interest.
33 . The method of claim 15 , further comprising further culturing said host cells under conditions such that a protein of interest encoded by said gene of interest is produced.
34 . The method of claim 33 , further comprising isolating said protein of interest.
35 . The method of claim 33 , wherein said culture conditions are selected from the group consisting of roller bottle cultures, perfusion cultures, batch fed cultures, and petri dish cultures.
36 . The method of claim 33 , wherein said host cells synthesize greater than about 1 picograms per cell per day of said protein of interest.
37 . The method of claim 33 , wherein said host cells synthesize greater than about 10 picograms per cell per day of said protein of interest.
38 . The method of claim 33 , wherein said host cells synthesize greater than about 50 picograms per cell per day of said protein of interest.
39 . A method of producing protein of interest comprising:
a) providing:
i) host cells; and
ii) a retroviral vector, said retroviral vector comprising in operable association an exogenous promoter, a gene of interest and an amplifiable marker;
b) contacting said host cells with said retroviral vector under conditions such that multiple copies of said retroviral vector integrate into the genome of said host cell to provide a transduced host cell;
c) culturing said transduced host cells under conditions that allow for amplification of said integrated retroviral vectors;
d) further culturing said host cells under conditions that allow for production of said protein of interest; and
e) purifying said protein of interest.
40 . The retroviral vector of claim 39 , wherein said amplifiable marker is selected from the group consisting of DHFR and glutamine synthetase.
41 . The method of claim 39 , wherein said culturing conditions in step c) comprise culturing said transduced host cells in the presence of a selection agent selected from the group consisting of methotrexate, phosphinothricin and methionine sulphoxime.
42 . The method of claim 41 , wherein said culturing conditions further comprises culturing said host cells in increasing concentrations of said selection agent.
43 . The retroviral vector of claim 39 , wherein said retroviral vector comprises MoMLV elements.
44 . The retroviral vector of claim 39 , wherein said retroviral vector further comprises an IRES element.
45 . The retroviral vector of claim 39 , wherein said retroviral vector comprises at least two genes of interest.
46 . The retroviral vector of claim 45 , wherein said at least two genes of interest are arranged in a polycistronic sequence.
47 . The retroviral vector of claim 46 , wherein said at least two genes of interest encode an immunoglobulin.
48 . The retroviral vector of claim 47 , wherein said immunoglobulins are selected from the group consisting of IgG, IgA, IgM, IgD, IbE and sIg.